Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF) (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $417000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 1337.93% to $417000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, up 765.19% year-over-year, with the annual reading at $1.4 million for FY2025, 1630.38% up from the prior year.
  • Depreciation & Amortization (CF) hit $417000.0 in Q4 2025 for ARS Pharmaceuticals, up from $391000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $417000.0 in Q4 2025 to a low of -$37000.0 in Q2 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $138947.4 across 5 years, with a median of $100000.0 in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): plummeted 117.7% in 2022 and later surged 2445.45% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $187000.0 in 2021, then tumbled by 92.51% to $14000.0 in 2022, then skyrocketed by 614.29% to $100000.0 in 2023, then tumbled by 71.0% to $29000.0 in 2024, then soared by 1337.93% to $417000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for SPRY at $417000.0 in Q4 2025, $391000.0 in Q3 2025, and $279000.0 in Q2 2025.